Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

(marketscreener.com) Program uses Denali’s Antibody Transport Vehicle technology to cross the blood-brain barrier and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 -- Biogen Inc.  and Denali Therapeutics Inc. today announced that Biogen has exercised the option to license Denali’s Antibody...https://www.marketscreener.com/quote/stock/DENALI-THERAPEUTICS-INC-40101989/news/Biogen-Exercises-Option-with-Denali-to-Develop-and-Commercialize-Antibody-Transport-Vehicle-Program-43475755/?utm_medium=RSS&utm_content=20230412